Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
Public ClinicalTrials.gov record NCT06531941. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism Who Completed the 12-Week Treatment Period in the Phase 2 Study, MBX-2H1002 Study (Avail-Ext)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
Study identification
- NCT ID
- NCT06531941
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- 400 µg of MBX 2109 once-weekly by subcutaneous injection Drug
- 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 30, 2024
- Primary completion
- May 26, 2027
- Completion
- May 26, 2027
- Last update posted
- Oct 27, 2025
2024 – 2027
United States locations
- U.S. sites
- 17
- U.S. states
- 9
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MBX Biosciences Investigational Site | Miami | Florida | 33033 | — |
| MBX Biosciences Investigational Site | Macon | Georgia | 31210 | — |
| MBX Biosciences Investigational Site | Jackson | Mississippi | 39202 | — |
| MBX Biosciences Investigational Site | St Louis | Missouri | 63110 | — |
| MBX Biosciences Investigational Site | Las Vegas | Nevada | 89148 | — |
| MBX Biosciences Investigational Site | Reno | Nevada | 89511 | — |
| MBX Biosciences Investigational Site | Albany | New York | 12203 | — |
| MBX Biosciences Investigational Site | New York | New York | 10032 | — |
| MBX Biosciences Investigational Site | The Bronx | New York | 10467 | — |
| MBX Biosciences Investigational Site | Columbus | Ohio | 43201 | — |
| MBX Biosciences Investigational Site | Dallas | Texas | 75208 | — |
| MBX Biosciences Investigational Site | El Paso | Texas | 79935 | — |
| MBX Biosciences Investigational Site | Fort Worth | Texas | 76132 | — |
| MBX Biosciences Investigational Site | Round Rock | Texas | 78681 | — |
| MBX Biosciences Investigational Site | San Antonio | Texas | 78231 | — |
| MBX Biosciences Investigational Site | Weslaco | Texas | 78596 | — |
| MBX Biosciences Investigational Site | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06531941, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2025 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06531941 live on ClinicalTrials.gov.